

# Special Issue

## Advances of Skin Disease

### Message from the Guest Editor

The skin represents the most exposed barrier of organisms, and, as such, has been the subject of intensive research focused on both neoplastic and inflammatory conditions. Recently, personalized therapies have gained attention not only on the scientific level, but also on the clinical level. These therapies have revolutionized oncology, with melanoma being the most explored cutaneous disease, by the use of new, cutting-edge treatments, including immunotherapies and targeted therapies. This proposed Special Issue aims to collect the most recent insights into clinical and translational research regarding melanoma, nonmelanoma skin neoplasms, and inflammatory cutaneous conditions. The scope of the research includes studies with novel diagnostic or therapeutic approaches that can result in more personalized and efficient cutaneous medicine, including molecular/cellular mechanisms, detection, stratification, surveillance, care management, or treatment of cutaneous diseases.

---

### Guest Editor

Dr. Jorge Feito

Pathology Department, Complejo Asistencial Universitario de Salamanca, 37007 Salamanca, Spain

---

### Deadline for manuscript submissions

closed (10 May 2023)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/118734](https://mdpi.com/si/118734)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).